It Took a Year, But It's Ready | ORCL Stock Analysis
1 extracted signal · 1 resolved · 0 still active
The Trade SetupIndependent analyst profile- Source published
- 23 Sept 2026, 19:06 UTC
- Recorded by Tahlil Plus
- 23 Sept 2026, 20:37 UTC
AI-generated source summary
The analysis of ORCL is based on a long-term wave count, suggesting that the price has completed a significant wave 3 correction. The current price action is interpreted as the beginning of wave 4, with a target projected towards the $211.48 level. This target aligns with the 78.60% Fibonacci retracement level of the preceding wave 1. The analysis implies that a break below $140.38 would invalidate this bullish outlook, indicating potential for deeper corrections, possibly to the 50% retracement level of $135.85. The failure bound of $140.38 is set below the significant 50% retracement of $135.85. The broader context suggests that the current movement is a part of a larger five-wave pattern, with the initial upward trend potentially reaching as high as $595.35 before a potential reversal.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Source processing completed
Source analysis and structured extraction completed.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
The Trade Setup
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.